The impact of an immuno-oncology service at a regional cancer centre based in the north west of the UK.
Br J Nurs
; 31(8): 414-420, 2022 Apr 21.
Article
in English
| MEDLINE | ID: covidwho-1791705
ABSTRACT
This article discusses the implementation and development of a centralised immuno-oncology service. As the indications and licensing of oncological immune checkpoint inhibitors (ICIs) expanded rapidly, they brought with them increasing challenges. The article evaluates the impact of an immuno-oncology service, focusing on the following areas admission rates due to immune-related adverse events (irAEs), number of bed days occupied due to immunotherapy toxicity and the incidence of Grade 3 and 4 (severe and life-threatening) irAEs. The article will also give an overview of patients requiring acute and subsequent management of toxicity as a percentage of the overall patients commenced on immunotherapy. The ultimate aim of the article is to highlight the importance of toxicity management and the overall benefits of a immuno-oncology service. The article will also discuss the impact of COVID-19 on the immuno-oncology service, highlighting the ways in which the team has adapted to the current environment to ensure high standards of patient care have been maintained.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Neoplasms, Second Primary
/
COVID-19
/
Neoplasms
Type of study:
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
Country/Region as subject:
Europa
Language:
English
Journal:
Br J Nurs
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS